Results from the phase III CONDOR trial, presented during the 2020 ASCO Virtual Scientific Program, showed that prostate specific membrane antigen (PSMA) 18F-DCFPyL-positron emission tomography (PET) scans demonstrated a correct localization rate (CLR) of 84.8-87.0% per 3 blinded independent readers, meeting the trial’s primary endpoint.
In an interview with CancerNetwork, Michael J. Morris, MD, prostate cancer section head at Memorial Sloan Kettering Cancer Center discussed a secondary endpoint of the trial – the change in treatment plans and patient care after completion of the scans.
Transcription:
So, the clinicians completed a questionnaire both before and after the performance of the PSMA scan to see if the PSMA scan changed their management. In 20% of those patients, that change in management was a change in goal of care, from a non-curative systemic therapy-based…
